{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:31:19Z","timestamp":1793107879930,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T00:00:00Z","timestamp":1501632000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s00404-017-4480-z","type":"journal-article","created":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T11:00:52Z","timestamp":1501671652000},"page":"661-677","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis"],"prefix":"10.1007","volume":"296","author":[{"given":"Yifeng","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8678-4277","authenticated-orcid":false,"given":"Qin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,2]]},"reference":[{"key":"4480_CR1","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1210\/jcem.84.6.5803","volume":"84","author":"E Carmina","year":"1999","unstructured":"Carmina E, Lobo RA (1999) Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 84:1897\u20131899","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"4480_CR2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1530\/EJE-10-0720","volume":"164","author":"CE Pepene","year":"2011","unstructured":"Pepene CE, Ilie IR, Marian I, Duncea I (2011) Circulating osteoprotegerin and soluble receptor activator of nuclear factor \u03baB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction. Eur J Endocrinol 164(1):61\u201368","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"4480_CR3","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.metabol.2009.02.005","volume":"58","author":"CJ Glueck","year":"2009","unstructured":"Glueck CJ, Morrison JA, Goldenberg N, Wang P (2009) Coronary heart disease risk factors in adult premenopausal white women with polycystic ovary syndrome compared with a healthy female population. Metab Clin Exp 58(5):714\u2013721","journal-title":"Metab Clin Exp"},{"key":"4480_CR4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1472-6823-12-9","volume":"12","author":"IR Ilie","year":"2012","unstructured":"Ilie IR, Marian I, Mocan T, Ilie R, Mocan L, Duncea I et al (2012) Ethinylestradiol30\u03bcg-drospirenone and metformin: could this combination improve endothelial dysfunction in polycystic ovary syndrome? BMC Endocr Disord 12:9","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"4480_CR5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2337\/diacare.22.1.141","volume":"22","author":"DA Ehrmann","year":"1999","unstructured":"Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J (1999) Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22(1):141\u2013146","journal-title":"Diabetes Care"},{"issue":"1","key":"4480_CR6","first-page":"165","volume":"84","author":"RS Legro","year":"1999","unstructured":"Legro RS, Kunselman AR, Dodson WC, Dunaif A (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84(1):165\u2013169","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"4480_CR7","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1210\/jcem.87.3.8305","volume":"87","author":"MR Palmert","year":"2002","unstructured":"Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A (2002) Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 87(3):1017\u20131023","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"4480_CR8","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1210\/jc.2003-032046","volume":"89","author":"R Azziz","year":"2004","unstructured":"Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO (2004) The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89(6):2745\u20132749","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"4480_CR9","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1056\/NEJMra041536","volume":"352","author":"DA Ehrmann","year":"2005","unstructured":"Ehrmann DA (2005) Polycystic ovary syndrome. N Engl J Med 352(12):1223\u20131236","journal-title":"N Engl J Med"},{"key":"4480_CR10","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1210\/jc.2013-2350","volume":"98","author":"RS Legro","year":"2013","unstructured":"Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK (2013) Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 98:4565\u20134592 (Online 1945-7197:1-29)","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"4480_CR11","first-page":"507","volume":"21","author":"P Froment","year":"2005","unstructured":"Froment P, Gizard F, Staels B, Dupont J, Monget P (2005) A role of PPARgamma in reproduction? Med Sci 21(5):507\u2013511","journal-title":"Med Sci"},{"key":"4480_CR12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00404-017-4422-9","volume":"296","author":"OE Anastasiou","year":"2017","unstructured":"Anastasiou OE, Canbay A, Fuhrer D, Reger-Tan S (2017) Metabolic and androgen profile in underweight women with polycystic ovary syndrome. Arch Gynecol Obstet 296:363\u2013371","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"4480_CR13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00404-014-3422-2","volume":"291","author":"M Doganay","year":"2015","unstructured":"Doganay M, Ozyer SS, Var T, Tonguc E, Gun Eryilmaz O, Ozer I et al (2015) Associations between adipocyte fatty acid-binding protein and clinical parameters in polycystic ovary syndrome. Arch Gynecol Obstet 291(2):447\u2013450","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"4480_CR14","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1095\/biolreprod66.1.190","volume":"66","author":"PD Schoppee","year":"2002","unstructured":"Schoppee PD, Garmey JC, Veldhuis JD (2002) Putative activation of the peroxisome proliferator-activated receptor gamma impairs androgen and enhances progesterone biosynthesis in primary cultures of porcine theca cells. Biol Reprod 66(1):190\u2013198","journal-title":"Biol Reprod"},{"key":"4480_CR15","first-page":"CD003053","volume":"1","author":"T Tang","year":"2010","unstructured":"Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH (2010) Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, d-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 1:CD003053","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"4480_CR16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1677\/joe.1.05844","volume":"184","author":"C Ortega-Gonz\u00e1lez","year":"2005","unstructured":"Ortega-Gonz\u00e1lez C, Cardoza L, Couti\u00f1o B, Hidalgo R, Arteaga-Troncoso G, Parra A (2005) Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. J Endocrinol 184(1):233\u2013239","journal-title":"J Endocrinol"},{"issue":"3","key":"4480_CR17","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1210\/jc.2004-1965","volume":"90","author":"C Ortega-Gonz\u00e1lez","year":"2005","unstructured":"Ortega-Gonz\u00e1lez C, Luna S, Hern\u00e1ndez L, Crespo G, Aguayo P, Arteaga-Troncoso G et al (2005) Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 90(3):1360\u20131365","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"4480_CR18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1365-2265.2008.03309.x","volume":"70","author":"LW Cho","year":"2009","unstructured":"Cho LW, Kilpatrick ES, Keevil BG, Coady AM, Atkin SL (2009) Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clin Endocrinol 70(2):233\u2013237","journal-title":"Clin Endocrinol"},{"issue":"1","key":"4480_CR19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.fertnstert.2010.06.058","volume":"95","author":"KK Naka","year":"2011","unstructured":"Naka KK, Kalantaridou SN, Kravariti M, Bechlioulis A, Kazakos N, Calis KA et al (2011) Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril 95(1):203\u2013209","journal-title":"Fertil Steril"},{"issue":"3","key":"4480_CR20","first-page":"390","volume":"28","author":"N Navali","year":"2012","unstructured":"Navali N, Shokoufe LA, Mallah F, Bastani P, Mashrabi O (2012) Comparing therapeutic effects of metformin and pioglitazone in polycystic ovary syndrome (PCOS). Pak J Med Sci 28(3):390\u2013394","journal-title":"Pak J Med Sci"},{"issue":"5","key":"4480_CR21","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s13224-012-0183-3","volume":"62","author":"S Sangeeta","year":"2012","unstructured":"Sangeeta S (2012) Metformin and pioglitazone in polycystic ovarian syndrome: a comparative study. J Obstet Gynecol India 62(5):551\u2013556","journal-title":"J Obstet Gynecol India"},{"issue":"1","key":"4480_CR22","first-page":"16","volume":"44","author":"A Ziaee","year":"2012","unstructured":"Ziaee A, Oveisi S, Abedini A, Hashemipour S, Karimzadeh T, Ghorbani A (2012) Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome. Acta Med Indones 44(1):16\u201322","journal-title":"Acta Med Indones"},{"issue":"6","key":"4480_CR23","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.psyneuen.2012.08.010","volume":"38","author":"L Kashani","year":"2013","unstructured":"Kashani L, Omidvar T, Farazmand B, Modabbernia A, Ramzanzadeh F, Tehraninejad ES et al (2013) Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. Psychoneuroendocrinology 38(6):767\u2013776","journal-title":"Psychoneuroendocrinology"},{"issue":"2","key":"4480_CR24","first-page":"574","volume":"10","author":"I Chaudhry","year":"2016","unstructured":"Chaudhry I, Sadaf Un N, Shams Un N (2016) Comparison between pioglitazone and metformin in terms of efficacy in patients with polycystic ovarian syndrome. Pak J Med Health Sci 10(2):574\u2013577","journal-title":"Pak J Med Health Sci"},{"issue":"6","key":"4480_CR25","doi-asserted-by":"crossref","first-page":"805","DOI":"10.4103\/2230-8210.192925","volume":"20","author":"K Shahebrahimi","year":"2016","unstructured":"Shahebrahimi K, Jalilian N, Bazgir N, Rezaei M (2016) Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome. Indian J Endocrinol Metab 20(6):805\u2013809","journal-title":"Indian J Endocrinol Metab"},{"issue":"12","key":"4480_CR26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.29252\/ijrm.14.12.743","volume":"14","author":"SM Sohrevardi","year":"2016","unstructured":"Sohrevardi SM, Nosouhi F, Khalilzade SH, Kafaie P, Karimi-Zarchi M, Halvaei I et al (2016) Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: an RCT. Int J Reprod BioMed 14(12):743\u2013754","journal-title":"Int J Reprod BioMed"},{"issue":"3","key":"4480_CR27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archpedi.160.3.241","volume":"160","author":"T Bridger","year":"2006","unstructured":"Bridger T, MacDonald S, Baltzer F, Rodd C (2006) Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med 160(3):241\u2013246","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"9","key":"4480_CR28","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1093\/humrep\/del185","volume":"21","author":"V Leo De","year":"2006","unstructured":"De Leo V, Musacchio MC, Morgante G, Piomboni P, Petraglia F (2006) Metformin treatment is effective in obese teenage girls with PCOS. Hum Reprod 21(9):2252\u20132256","journal-title":"Hum Reprod"},{"issue":"6","key":"4480_CR29","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1600-0412.2012.01385.x","volume":"91","author":"GS Ghazeeri","year":"2012","unstructured":"Ghazeeri GS, Nassar AH, Younes Z, Awwad JT (2012) Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview. Acta Obstet Gynecol Scand 91(6):658\u2013678","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"2","key":"4480_CR30","first-page":"210","volume":"68","author":"HY Waki","year":"2010","unstructured":"Waki HY, Yamauchi T, Kadowaki T (2010) Regulation of differentiation and hypertrophy of adipocytes and adipokine network by PPARgamma. Nihon Rinsho 68(2):210\u2013216","journal-title":"Nihon Rinsho"},{"issue":"7","key":"4480_CR31","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1172\/JCI0215634","volume":"110","author":"D Panigrahy","year":"2002","unstructured":"Panigrahy D, Singer S, Shen LQ et al (2002) PPAR\u03b3 ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110(7):923\u2013932","journal-title":"J Clin Invest"},{"issue":"3","key":"4480_CR32","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2015.7996","volume":"314","author":"JD Lewis","year":"2015","unstructured":"Lewis JD, Habel LA, Quesenberry CP, Strom BL, Peng T, Hedderson MM et al (2015) Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 314(3):265\u2013277","journal-title":"JAMA"},{"issue":"3","key":"4480_CR33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00125-014-3456-9","volume":"58","author":"D Levin","year":"2015","unstructured":"Levin D, Bell S, Sund R, Hartikainen SA, Tuomilehto J, Pukkala E et al (2015) Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 58(3):493\u2013504","journal-title":"Diabetologia"},{"issue":"1","key":"4480_CR34","doi-asserted-by":"crossref","first-page":"e85479","DOI":"10.1371\/journal.pone.0085479","volume":"9","author":"MY Lee","year":"2014","unstructured":"Lee MY, Hsiao PJ, Yang YH, Lin KD, Shin SJ (2014) The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease. PLoS One 9(1):e85479","journal-title":"PLoS One"},{"issue":"3","key":"4480_CR35","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4103\/2230-8210.131223","volume":"18","author":"V Balaji","year":"2014","unstructured":"Balaji V, Seshiah V, Ashtalakshmi G, Ramanan SG, Janarthinakani M (2014) A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population. Indian J Endocrinol Metab 18(3):425\u2013427","journal-title":"Indian J Endocrinol Metab"},{"issue":"1","key":"4480_CR36","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2125.2012.04325.x","volume":"75","author":"L Wei","year":"2013","unstructured":"Wei L, MacDonald TM, Mackenzie IS (2013) Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol 75(1):254\u2013259","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"4480_CR37","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40261-013-0106-9","volume":"33","author":"C Vallarino","year":"2013","unstructured":"Vallarino C, Perez A, Fusco G, Liang H, Bron M, Manne S et al (2013) Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights. Clin Drug Investig 33(9):621\u2013631","journal-title":"Clin Drug Investig"},{"issue":"2","key":"4480_CR38","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2337\/dc11-1449","volume":"35","author":"CH Tseng","year":"2012","unstructured":"Tseng CH (2012) Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 35(2):278\u2013280","journal-title":"Diabetes Care"},{"issue":"6","key":"4480_CR39","doi-asserted-by":"crossref","first-page":"462","DOI":"10.4093\/dmj.2012.36.6.462","volume":"36","author":"SO Song","year":"2012","unstructured":"Song SO, Kim KJ, Lee BW (2012) Response: the risk of bladder cancer in korean diabetic subjects treated with pioglitazone (diabetes metab j 2012;36:371\u20138). Diabetes Metab J 36(6):462\u2013463","journal-title":"Diabetes Metab J"},{"key":"4480_CR40","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/pds.4154","volume":"26","author":"C Hampp","year":"2017","unstructured":"Hampp C, Pippins J (2017) Pioglitazone and bladder cancer: FDA\u2019s assessment. Pharmacoepidemiol Drug Saf 26:117\u2013118","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"4480_CR41","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/dom.12608","volume":"18","author":"E Erdmann","year":"2016","unstructured":"Erdmann E, Harding S, Lam H, Perez A (2016) Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes. Diabetes Obes Metab 18(3):266\u2013273","journal-title":"Diabetes Obes Metab"},{"key":"4480_CR42","doi-asserted-by":"crossref","first-page":"i1541","DOI":"10.1136\/bmj.i1541","volume":"352","author":"M Tuccori","year":"2016","unstructured":"Tuccori M, Filion KB, Yin H, Yu OH, Platt RW, Azoulay L (2016) Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ 352:i1541","journal-title":"BMJ"},{"issue":"2","key":"4480_CR43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4158\/EP161682.CS","volume":"23","author":"AJ Garber","year":"2017","unstructured":"Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA et al (2017) Consensus statement by the American Association Of Clinical Endocrinologists and American College of endocrinology on the comprehensive type 2 diabetes management algorithm\u20142017 executive summary. Endocr Pract 23(2):207\u2013238","journal-title":"Endocr Pract"},{"issue":"12","key":"4480_CR44","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1210\/jc.2013-2350","volume":"98","author":"RS Legro","year":"2013","unstructured":"Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R et al (2013) Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 98(12):4565\u20134592","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"4480_CR45","doi-asserted-by":"crossref","first-page":"E930","DOI":"10.1152\/ajpendo.00522.2004","volume":"288","author":"N Rasouli","year":"2005","unstructured":"Rasouli N, Raue U, Miles LM, Lu T, Di Gregorio GB, Elbein SC et al (2005) Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab 288(5):E930\u2013E934","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"5","key":"4480_CR46","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jdiacomp.2009.05.004","volume":"24","author":"AK Gupta","year":"2010","unstructured":"Gupta AK, Bray GA, Greenway FL, Martin CK, Johnson WD, Smith SR (2010) Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes. J Diabetes Complicat 24(5):289\u2013296","journal-title":"J Diabetes Complicat"},{"issue":"4","key":"4480_CR47","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1210\/jc.2009-0911","volume":"95","author":"M Bajaj","year":"2010","unstructured":"Bajaj M, Baig R, Suraamornkul S, Hardies LJ, Coletta DK, Cline GW et al (2010) Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 95(4):1916\u20131923","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"4480_CR48","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1001\/jama.2015.3656","volume":"313","author":"LA Stewart","year":"2015","unstructured":"Stewart LA, Clarke M, Rovers M et al (2015) Preferred Reporting Items for a systematic review and meta-analysis of individual participant data: The PRISMA-IPD Statement. JAMA 313(16):1657\u20131665. doi: 10.1001\/jama.2015.3656","journal-title":"JAMA"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-017-4480-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-017-4480-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-017-4480-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T19:43:39Z","timestamp":1569959019000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-017-4480-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,2]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["4480"],"URL":"https:\/\/doi.org\/10.1007\/s00404-017-4480-z","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,2]]}}}